Compass Pathways | Company Profile
NASDAQ: CMPS
Latest Sector Updates
Compass is a mental healthcare company dedicated to providing access to innovations in mental health treatment. The company is running a large-scale clinical development programme of psilocybin therapy for depression. Their phase IIb study for treatment- resistant depression is being run across Europe and North America. Compass was granted ‘breakthrough therapy’ designation by the US Food and Drug Administration (FDA) for their research into the use of psilocybin for severe depression.
Compass IPO’s in September 2020 on the Nasdaq raising US$127.5m.
Stock information
Contact Information
Website: https://compasspathways.com
Contact Email:ir@compasspathways.com
Corporate Presentation Link: click here
Latest Compass Pathways News
COMPASS Pathways granted fifth US patent for crystalline psilocybin
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that ...
COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
Highlights: - Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021 - ...
COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021
COMPASS Pathways plc (Nasdaq:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will ...
COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor conferences
COMPASS Pathways plc (Nasdaq:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of ...
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
London, UK – 21 July 2021 COMPASS Pathways plc (Nasdaq:CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in ...
COMPASS Pathways to participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit
COMPASS Pathways plc (Nasdaq:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Lars Wilde, ...
